Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme.

Tivnan, Amanda; Zakaria, Zaitun; O'Leary, Caitrín; Kögel, Donat; Pokorny, Jenny L; Sarkaria, Jann N; Prehn, Jochen H M

Tivnan, Amanda; Zakaria, Zaitun; O'Leary, Caitrín; Kögel, Donat; Pokorny, Jenny L; Sarkaria, Jann N; Prehn, Jochen H M.

Afiliación

Tivnan A; Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland Dublin, Ireland.
Zakaria Z; Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland Dublin, Ireland.
O'Leary C; Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland Dublin, Ireland.
Kögel D; Experimental Neurosurgery, Neuroscience Center, Frankfurt University Hospital Frankfurt am Main, Germany.
Pokorny JL; Department of Radiation Oncology, Mayo Clinic Rochester, MN, USA.
Sarkaria JN; Department of Radiation Oncology, Mayo Clinic Rochester, MN, USA.
Prehn JH; Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland Dublin, Ireland.

Front Neurosci ; 9: 218, 2015.

Article en En | MEDLINE | ID: mdl-26136652

Palabras clave

chemoresistance; glioblastoma; multidrug resistance protein 1; siRNA

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Neurosci Año: 2015 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Neurosci Año: 2015 Tipo del documento: Article